chartexchange

RGLS
Regulus Therapeutics Inc.
stockNASDAQ

InactiveJun 24, 2025
8.16USD+0.246%(+0.02)9,342,413
Loading…
Loading…
Sector
Healthcare
Industry
Biotechnology
CEO
Joseph Hagan
HQ
San Diego, California, USA
Jun 29, 2022 · 1-for-10 (reverse)
RGLS Profile

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg

RGLS Performance
PeriodPriceDateChange